MAPK8 and cervical cancer: The anticancer activity of OA combined with esculetin against cervical cancer was tested in vitro by Edthara et al.; OA has been reported to inhibit the major signaling pathways like PI3K, Akt, ERK/JNK/p38, mTOR, NF-kB, and S6K, while esculetin was reported to induce cell death by activating various pathways such as JNK, ERK, Caspase-3, and NF-kB (Figure 10).